Printer Friendly

Karmanos Cancer Institute, Aastrom Biosciences create new center for cell therapy.

The Barbara Ann Karmanos Cancer Institute at Wayne State University in Detroit, MI, and Aastrom Biosciences, Inc., Ann Arbor, MI, have joined to establish the Center for Cell Therapy (CCT). The CCT is initially being funded through a LLL#2.2 million grant awarded from the Michigan Economic Development Corporation, by the Michigan Life Sciences Corridor Initiative, along with other contributions from the Institute and Aastrom. The CCT will focus on the development of new cell therapies to treat cancer and other debilitating diseases.

The goal of the CCT is to consolidate resources to enable cell therapies to be developed and delivered to cancer patients. The CCT will begin clinical studies with the Aastrom Replicell System using cord blood-derived cells intended to provide a normal blood and immune system in leukemia patients. The CCT will also initiate a project using the Aastrom system and Dendricell cell produce to produce dendritic cell-based vaccines intended to treat cancer.

Contact: Martha Button, Institute - (313) 996-8674, or Todd Simpson, Aastrom - (734) 930-5777
COPYRIGHT 2001 Transplant Communications, Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2001 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Comment:Karmanos Cancer Institute, Aastrom Biosciences create new center for cell therapy.
Publication:Transplant News
Article Type:Brief Article
Geographic Code:1USA
Date:Jul 13, 2001
Previous Article:World Heart announces it will receive approval to market Novacor LVAS in Japan.
Next Article:Fujisawa obtains worldwide rights to Aventis' MNA compound.

Related Articles
Aastrom awarded NIH grant for cord blood transplant program.
Aastrom enters distribution agreements with Gambro and Micromin to distribute AastromReplicell System.
Aastrom Biosciences, Loyola University perform first ever transplants of ex vivo produced stem cells in cancer patients.
Aastrom Biosciences initiates new product program for treatment of bone related diseases.
Aastrom Biosciences begins study of new stem cell transplant procedure in leukemia patients.
Aastrom Biosciences begins controlled clinical trial for cord blood therapy in leukemia patients.
Aastrom receives patent covering integrated system for producing human cells.
Monogram and Dana-Farber enter collaboration agreement.

Terms of use | Privacy policy | Copyright © 2022 Farlex, Inc. | Feedback | For webmasters |